Profile - To The Moon

Mouni

Posts · 5Posts · 5
Following · 0Following · 0
Followers · 0Followers · 0

- MouniMouni
  ·2022-07-14
  Though approved no jump in price 😐
  US FDA Authorises Novavax Covid-19 Vaccine for Adults
  (REUTERS) - The US Food and Drug Administration (FDA) authorised the use of Novavax Inc's Covid-19 v
  US FDA Authorises Novavax Covid-19 Vaccine for Adults
  153 Comment
  Like
  Share
  Report
- MouniMouni
  ·2022-06-07
  $Novavax(NVAX)$Why the stock is suspended
  1.75K Comment
  6
  Share
  Report
- MouniMouni
  ·2022-03-12
  $Futu Holdings Limited(FUTU)$Futu Holdings Limited Q4 Financial Results: 2021 Revenues Up 114.9% YoY With 17 Million Users Worldwide
  445 Comment
  1
  Share
  Report
- MouniMouni
  ·2022-02-14
  $Novavax(NVAX)$Singapore's Health Sciences Authority (HSA) said on Monday it has granted an interim authorisation for Novavax's COVID-19 vaccine.T
  1.01K Comment
  18
  Share
  Report
- MouniMouni
  ·2021-12-28
  $Novavax(NVAX)$Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, today announced that the Drugs Controller General of India (DCGI) has granted emergency use authorization (EUA) for Novavax' recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant. The vaccine will be manufactured and marketed in India by SII under the brand name Covovax™.
  489 Comment
  1
  Share
  Report
No following yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3586149580438296","uuid":"3586149580438296","gmtCreate":1623059948234,"gmtModify":1623059948234,"name":"Mouni","pinyin":"mouni","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":6,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.32%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.85%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9076920299,"gmtCreate":1657774410011,"gmtModify":1676536060420,"author":{"id":"3586149580438296","authorId":"3586149580438296","name":"Mouni","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586149580438296","idStr":"3586149580438296"},"themes":[],"htmlText":"Though approved no jump in price 😐","listText":"Though approved no jump in price 😐","text":"Though approved no jump in price 😐","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9076920299","repostId":"2251024162","repostType":2,"repost":{"id":"2251024162","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1657756140,"share":"https://ttm.financial/m/news/2251024162?lang=&edition=fundamental","pubTime":"2022-07-14 07:49","market":"us","language":"en","title":"US FDA Authorises Novavax Covid-19 Vaccine for Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2251024162","media":"Reuters","summary":"(REUTERS) - The US Food and Drug Administration (FDA) authorised the use of Novavax Inc's Covid-19 v","content":"<html><head></head><body><p>(REUTERS) - The US Food and Drug Administration (FDA) authorised the use of Novavax Inc&#39;s Covid-19 vaccine on Wednesday (July 13), clearing the way for a shot whose more traditional technology has raised hopes of wider acceptance among vaccine skeptics.</p><p>Shares of Novavax rose 1.3 per cent to US$70.89 after its two-dose vaccine became the fourth Covid-19 shot to be authorised for use in adults in the United States.</p><p>The US Centres for Disease Control and Prevention (CDC) still needs to sign off on the use of the vaccine before it can be made available to people.</p><p>A panel of CDC advisers on vaccines is expected to meet on Tuesday, but the agenda has not been released yet.</p><p>Earlier this week, the US government said it had secured 3.2 million Novavax vaccine doses, which it plans to release once the company finishes quality testing in the next few weeks.</p><p>More than two-thirds of the US population has been fully vaccinated with shots from Moderna Inc, Pfizer-BioNTech or Johnson &amp; Johnson.</p><p>US health officials hope that people who have opted not to take Pfizer and Moderna&#39;s vaccine, which are based on the groundbreaking messenger RNA (mRNA) technology, will instead opt for Novavax&#39;s protein-based shot.</p><p>The vaccine, already approved in Europe, is based on a technology that has been used for decades to combat diseases including hepatitis B and influenza.</p><p>&#34;Today&#39;s authorisation offers adults in the United States who have not yet received a Covid-19 vaccine another option that meets the FDA&#39;s rigorous standards,&#34; FDA Commissioner Robert Califf said in a statement.</p><p>In Europe, however, demand for the shot has not been significantly high, with about 242,000 doses of the vaccine administered since its launch in December, prompting Novavax to increase its focus on lower-income countries.</p><p>The company&#39;s initial application for US authorisation of the shot was delayed by almost a year on development and production problems, making it a late entrant in the country&#39;s market for Covid vaccines.</p><p>Novavax has projected between US$4 billion (S$5.62 billion) and US$5 billion in sales this year. Analysts expect sales at the lower end of that range, according to Refinitiv.</p><p>More On This TopicUS authorities flag risk of heart inflammation from Novavax Covid-19 vaccineNovavax&#39;s Covid-19 vaccine shows long-term efficacy in UK trial</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US FDA Authorises Novavax Covid-19 Vaccine for Adults</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS FDA Authorises Novavax Covid-19 Vaccine for Adults\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-07-14 07:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>(REUTERS) - The US Food and Drug Administration (FDA) authorised the use of Novavax Inc&#39;s Covid-19 vaccine on Wednesday (July 13), clearing the way for a shot whose more traditional technology has raised hopes of wider acceptance among vaccine skeptics.</p><p>Shares of Novavax rose 1.3 per cent to US$70.89 after its two-dose vaccine became the fourth Covid-19 shot to be authorised for use in adults in the United States.</p><p>The US Centres for Disease Control and Prevention (CDC) still needs to sign off on the use of the vaccine before it can be made available to people.</p><p>A panel of CDC advisers on vaccines is expected to meet on Tuesday, but the agenda has not been released yet.</p><p>Earlier this week, the US government said it had secured 3.2 million Novavax vaccine doses, which it plans to release once the company finishes quality testing in the next few weeks.</p><p>More than two-thirds of the US population has been fully vaccinated with shots from Moderna Inc, Pfizer-BioNTech or Johnson &amp; Johnson.</p><p>US health officials hope that people who have opted not to take Pfizer and Moderna&#39;s vaccine, which are based on the groundbreaking messenger RNA (mRNA) technology, will instead opt for Novavax&#39;s protein-based shot.</p><p>The vaccine, already approved in Europe, is based on a technology that has been used for decades to combat diseases including hepatitis B and influenza.</p><p>&#34;Today&#39;s authorisation offers adults in the United States who have not yet received a Covid-19 vaccine another option that meets the FDA&#39;s rigorous standards,&#34; FDA Commissioner Robert Califf said in a statement.</p><p>In Europe, however, demand for the shot has not been significantly high, with about 242,000 doses of the vaccine administered since its launch in December, prompting Novavax to increase its focus on lower-income countries.</p><p>The company&#39;s initial application for US authorisation of the shot was delayed by almost a year on development and production problems, making it a late entrant in the country&#39;s market for Covid vaccines.</p><p>Novavax has projected between US$4 billion (S$5.62 billion) and US$5 billion in sales this year. Analysts expect sales at the lower end of that range, according to Refinitiv.</p><p>More On This TopicUS authorities flag risk of heart inflammation from Novavax Covid-19 vaccineNovavax&#39;s Covid-19 vaccine shows long-term efficacy in UK trial</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2251024162","content_text":"(REUTERS) - The US Food and Drug Administration (FDA) authorised the use of Novavax Inc's Covid-19 vaccine on Wednesday (July 13), clearing the way for a shot whose more traditional technology has raised hopes of wider acceptance among vaccine skeptics.Shares of Novavax rose 1.3 per cent to US$70.89 after its two-dose vaccine became the fourth Covid-19 shot to be authorised for use in adults in the United States.The US Centres for Disease Control and Prevention (CDC) still needs to sign off on the use of the vaccine before it can be made available to people.A panel of CDC advisers on vaccines is expected to meet on Tuesday, but the agenda has not been released yet.Earlier this week, the US government said it had secured 3.2 million Novavax vaccine doses, which it plans to release once the company finishes quality testing in the next few weeks.More than two-thirds of the US population has been fully vaccinated with shots from Moderna Inc, Pfizer-BioNTech or Johnson & Johnson.US health officials hope that people who have opted not to take Pfizer and Moderna's vaccine, which are based on the groundbreaking messenger RNA (mRNA) technology, will instead opt for Novavax's protein-based shot.The vaccine, already approved in Europe, is based on a technology that has been used for decades to combat diseases including hepatitis B and influenza.\"Today's authorisation offers adults in the United States who have not yet received a Covid-19 vaccine another option that meets the FDA's rigorous standards,\" FDA Commissioner Robert Califf said in a statement.In Europe, however, demand for the shot has not been significantly high, with about 242,000 doses of the vaccine administered since its launch in December, prompting Novavax to increase its focus on lower-income countries.The company's initial application for US authorisation of the shot was delayed by almost a year on development and production problems, making it a late entrant in the country's market for Covid vaccines.Novavax has projected between US$4 billion (S$5.62 billion) and US$5 billion in sales this year. Analysts expect sales at the lower end of that range, according to Refinitiv.More On This TopicUS authorities flag risk of heart inflammation from Novavax Covid-19 vaccineNovavax's Covid-19 vaccine shows long-term efficacy in UK trial","news_type":1},"isVote":1,"tweetType":1,"viewCount":153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9051088186,"gmtCreate":1654609389245,"gmtModify":1676535477482,"author":{"id":"3586149580438296","authorId":"3586149580438296","name":"Mouni","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586149580438296","idStr":"3586149580438296"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>Why the stock is suspended&nbsp;","listText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>Why the stock is suspended&nbsp;","text":"$Novavax(NVAX)$Why the stock is suspended","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9051088186","isVote":1,"tweetType":1,"viewCount":1751,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9036643122,"gmtCreate":1647082806427,"gmtModify":1676534194018,"author":{"id":"3586149580438296","authorId":"3586149580438296","name":"Mouni","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586149580438296","idStr":"3586149580438296"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>Futu Holdings Limited Q4 Financial Results: 2021 Revenues Up 114.9% YoY With 17 Million Users Worldwide","listText":"<a href=\"https://ttm.financial/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>Futu Holdings Limited Q4 Financial Results: 2021 Revenues Up 114.9% YoY With 17 Million Users Worldwide","text":"$Futu Holdings Limited(FUTU)$Futu Holdings Limited Q4 Financial Results: 2021 Revenues Up 114.9% YoY With 17 Million Users Worldwide","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9036643122","isVote":1,"tweetType":1,"viewCount":445,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9095190642,"gmtCreate":1644845965989,"gmtModify":1676533967163,"author":{"id":"3586149580438296","authorId":"3586149580438296","name":"Mouni","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586149580438296","idStr":"3586149580438296"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>Singapore's Health Sciences Authority (HSA) said on Monday it has granted an interim authorisation for Novavax's COVID-19 vaccine.T","listText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>Singapore's Health Sciences Authority (HSA) said on Monday it has granted an interim authorisation for Novavax's COVID-19 vaccine.T","text":"$Novavax(NVAX)$Singapore's Health Sciences Authority (HSA) said on Monday it has granted an interim authorisation for Novavax's COVID-19 vaccine.T","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":18,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095190642","isVote":1,"tweetType":1,"viewCount":1010,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9009246300,"gmtCreate":1640704689454,"gmtModify":1676533535440,"author":{"id":"3586149580438296","authorId":"3586149580438296","name":"Mouni","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586149580438296","idStr":"3586149580438296"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, today announced that the Drugs Controller General of India (DCGI) has granted emergency use authorization (EUA) for Novavax' recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant. The vaccine will be manufactured and marketed in India by SII under the brand name Covovax™.","listText":"<a href=\"https://ttm.financial/S/NVAX\">$Novavax(NVAX)$</a>Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, today announced that the Drugs Controller General of India (DCGI) has granted emergency use authorization (EUA) for Novavax' recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant. The vaccine will be manufactured and marketed in India by SII under the brand name Covovax™.","text":"$Novavax(NVAX)$Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, today announced that the Drugs Controller General of India (DCGI) has granted emergency use authorization (EUA) for Novavax' recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant. The vaccine will be manufactured and marketed in India by SII under the brand name Covovax™.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009246300","isVote":1,"tweetType":1,"viewCount":489,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":true}